Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Novartis Pharmaceuticals
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
MarketScan® secukinumab cohort:
Included patients with at least 1 secukinumab claim between 01 January 2015 and 30 June 2020 (index date is the first secukinumab claim)
Included patients age ≥18 years as of the year of index date
Included patients with at least 1 non-ruleout psoriasis diagnosis during 2 years of pre-index period
Included patients with continuous medical/pharmacy coverage in the 2-year pre-index period
Included patients with continuous medical/pharmacy coverage in the 1-year post-index period
Included non-switched patients with secukinumab treatment on or after the enrollment between 01 January 2017 to 01 September 2020
* Non-switched patients are those who did not use other biologics/apremilast treatments on the enrollment date
* Index date will be the date of the first secukinumab treatment date
Included patients with age ≥ 18 on the index date
Included patients with psoriasis diagnosis in the pre-index period and index date
Included patients with ≥ 1 year follow-up period
* Follow-up period is the gap between patient's last visit date and index date
You may not be if
Excluded patients with any psoriatic arthritis diagnosis during 2 years to 5 years pre-index period, as well as on the index date
Excluded patients with any biologics/apremilast including secukinumab claim during the 2-year pre-index (excluding index date)
Excluded patients received other non-secukinumab biologics/apremilast during 6 months post index date period (including index date) (This criterion is only applicable for the secukinumab cohort)
BADBIR cohort:
Excluded patients with psoriatic arthritis (PsA) prior to and on index date
Excluded patients with any biologics/apremilast including secukinumab in the baseline period
